Brenda O’Connell
0000-0001-6234-6435
Publication & Citation Trends
Most Cited Works
Publications
84 total
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment PDF
Cited by 48
OpenAlex
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial PDF
Cited by 72
OpenAlex
Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
Cited by 23
OpenAlex
Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.
Cited by 55
OpenAlex
An OBSL1-Cul7Fbxw8 Ubiquitin Ligase Signaling Mechanism Regulates Golgi Morphology and Dendrite Patterning PDF
Cited by 102
OpenAlex
A Genome-wide Camptothecin Sensitivity Screen Identifies a Mammalian MMS22L-NFKBIL2 Complex Required for Genomic Stability PDF
Cited by 123
OpenAlex
Mammalian BTBD12/SLX4 Assembles A Holliday Junction Resolvase and Is Required for DNA Repair PDF
Cited by 448
OpenAlex
Mammalian BTBD12/SLX4 Assembles A Holliday Junction Resolvase and Is Required for DNA Repair
Cited by 25
OpenAlex
哺乳類BTBD12/SLX4はホリデイジャンクションリゾルバーゼを集め,DNA修復に必要である。
Cited by 0
Semantic Scholar
Research Topics
PI3K/AKT/mTOR signaling in cancer
(54)
Chronic Lymphocytic Leukemia Research
(46)
Lung Cancer Treatments and Mutations
(25)
Advanced Breast Cancer Therapies
(17)
Ubiquitin and proteasome pathways
(10)
Frequent Co-Authors
Affiliations
Harvard University
Johns Hopkins University
Tel Aviv University
Brown University
Johns Hopkins Medicine